ASHEVILLE, N.C., July 23,
2024 /PRNewswire/ -- Genova Diagnostics, a pioneer in
gut health and nutritional laboratory testing, proudly announces
the launch of the Fatty15 Test, in collaboration with Seraphina
Therapeutics. This unique offering assesses pentadecanoic acid
(C15:0), a newly established essential fatty acid.
Dr. Stephanie Venn-Watson, the
foremost expert on C15:0, has demonstrated its critical role in
combating Cellular Fragility Syndrome, a condition characterized by
weakened cell membranes and susceptibility to diseases like type 2
diabetes, heart disease, and nonalcoholic fatty liver disease.
"Health starts at the cellular level," emphasizes Dr. Venn-Watson.
"By strengthening cell membranes and mitigating lipid peroxidation,
C15:0 supports mitochondrial function, regulates metabolic
pathways, and enhances overall healthspan."
"Genova Diagnostics is excited to be collaborating with
Seraphina Therapeutics on this unique project," says Jeff Ledford, CEO of Genova Diagnostics. "Dr.
Venn-Watson's research has brought tremendous excitement and
attention to the importance of individual fatty acids in the
spectrum of human health."
The at-home Fatty15 Test, available through Genova Connect,
assesses C15:0 levels using a simple fingerstick blood sample. It
provides data on cellular health, informing decisions about dietary
and supplementation needs. This collaboration highlights
Genova's commitment to making
cutting-edge health diagnostics more accessible and promoting
proactive health management.
In addition to the consumer-focused Fatty15 Test, Genova has long offered the Essential and
Metabolic Fatty Acids (EMFA) profile to healthcare providers,
offering a comprehensive evaluation of a wide range of fatty acids,
including C15:0.
"Genova is dedicated to
advancing health through innovative partnerships and scientific
research," says Ledford. "The Fatty15 Test exemplifies our
commitment to expanding the availability of essential testing and
promoting optimal health."
Genova is broadening its
support from functional and integrative healthcare providers to a
wider range of medical professionals and consumers. "We are
extending the benefits of our cutting-edge diagnostics beyond niche
communities," Ledford says. This strategic move aims to enhance
health and well-being of the larger population.
About Genova Diagnostics
Genova Diagnostics is a
leading provider of clinical laboratory testing, offering
comprehensive panels that help practitioners and individuals create
treatment plans for optimal health outcomes. For more information,
visit gdx.net or connect.gdx.net.
About Seraphina Therapeutics
Seraphina Therapeutics,
Inc. is dedicated to advancing global health through the discovery
of essential fatty acids and micronutrient therapeutics. Seraphina
develops innovative supplements, food fortifiers, and nutritional
interventions to enhance cellular function and promote longevity.
For more information, visit DiscoverC15.com and fatty15.com.
CONTACT: Info@gdx.net
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genova-diagnostics-launches-at-home-fatty15-test-302203956.html
SOURCE Genova Diagnostics, Inc.